Rain Ther­a­peu­tics head­lines newest slate of IPO-bound biotechs with $100M pen­ciled in for lead on­col­o­gy pro­gram

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

A fresh slate of biotech IPOs has filed to go pub­lic as the cal­en­dar turns to­ward the sec­ond quar­ter.

Three com­pa­nies filed their reg­is­tra­tional pa­per­work over the hol­i­day week­end, with Rain Ther­a­peu­tics and Im­pel Neu­roPhar­ma sub­mit­ting S-1s on Fri­day and Aneb­u­lo Phar­ma­ceu­ti­cals do­ing so last Thurs­day. Rain leads the es­ti­mat­ed rais­es of the group with a $100 mil­lion tranche pen­ciled in, fol­lowed by Im­pel at $75 mil­lion and Aneb­u­lo at a mod­est $15 mil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.